Literature DB >> 9643619

Assessment of hepatic blood flow using continuous infusion of high clearance drugs.

R C Schoemaker1, J Burggraaf, A F Cohen.   

Abstract

AIMS: To provide methods for the translation of the concentration-time profile of highly cleared marker compounds into the underlying clearance and hepatic blood flow profile.
METHODS: Continuous infusion of indocyanine green or sorbitol was used to assess the effect of the hepatic blood flow modifiers exercise, somatostatin and octreotide. Three distinct methods are described for the translation of concentration into flow: 1. assuming successive phases of constant clearance 2. point to point estimation of clearance using estimates of concentration change 3. using a parametric description of the flow profile in combination with the differential equations describing the change in marker concentrations.
RESULTS: The marker compound concentration profiles are adequately described using the different methods. Exercise results in a decrease in hepatic blood flow of about 80%. Somatostatin and octreotide elicit an indistinguishable hepatic blood flow decrease from 1.49 to 1.07 l min(-1). Return to baseline takes much longer for octreotide (half-life 126+/-104 min) than for somatostatin (half-life 4.29+/-3.55 min).
CONCLUSIONS: Translation of concentration profiles into clearance profiles is possible making continuous assessment of hepatic blood flow feasible.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9643619      PMCID: PMC1873547          DOI: 10.1046/j.1365-2125.1998.00711.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

Review 2.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

3.  Estimating impossible curves using NONMEM.

Authors:  R C Schoemaker; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1996-09       Impact factor: 4.335

4.  Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects.

Authors:  G E Sonnenberg; U Keller; A Perruchoud; D Burckhardt; K Gyr
Journal:  Gastroenterology       Date:  1981-03       Impact factor: 22.682

5.  Influence of 1-desamino-8-D-vasopressin on endogenous fibrinolysis, haemodynamics and liver blood flow in healthy subjects.

Authors:  J Burggraaf; H C Schoemaker; J M Kroon; L Huisman; C Kluft; A F Cohen
Journal:  Clin Sci (Lond)       Date:  1994-05       Impact factor: 6.124

6.  Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.

Authors:  K S Pang; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

7.  Physiological and pharmacological variability in estimated hepatic blood flow in man.

Authors:  T K Daneshmend; L Jackson; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

8.  Influence of somatostatin on splanchnic glucose metabolism in postabsorptive and 60-hour fasted humans.

Authors:  J Wahren; S Efendić; R Luft; L Hagenfeldt; O Björkman; P Felig
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

9.  Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green.

Authors:  P A Soons; A De Boer; A F Cohen; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

10.  The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis.

Authors:  J Wahren; L S Eriksson
Journal:  Scand J Gastroenterol Suppl       Date:  1986
View more
  8 in total

1.  Persistent splanchnic hyperemia during upright tilt in postural tachycardia syndrome.

Authors:  Julian M Stewart; Marvin S Medow; June L Glover; Leslie D Montgomery
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-02       Impact factor: 4.733

2.  Changes in regional blood volume and blood flow during static handgrip.

Authors:  Julian M Stewart; Leslie D Montgomery; June L Glover; Marvin S Medow
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-08-25       Impact factor: 4.733

3.  Splanchnic hyperemia and hypervolemia during Valsalva maneuver in postural tachycardia syndrome.

Authors:  Julian M Stewart; Marvin S Medow; Leslie D Montgomery; June L Glover; Mark M Millonas
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-06-17       Impact factor: 4.733

Review 4.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

5.  The effect of food on the high clearance drug asenapine after sublingual administration to healthy male volunteers.

Authors:  Peter Dogterom; Rik de Greef; Pierre A M Peeters
Journal:  Eur J Clin Pharmacol       Date:  2015-01-01       Impact factor: 2.953

6.  Sensitive LC MS quantitative analysis of carbohydrates by Cs+ attachment.

Authors:  Eduard Rogatsky; Harsha Jayatillake; Gayotri Goswami; Vlad Tomuta; Daniel Stein
Journal:  J Am Soc Mass Spectrom       Date:  2005-09-22       Impact factor: 3.109

7.  Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients.

Authors:  Mariska Y M Peeters; Leon P H J Aarts; Ferenc A Boom; Leo J Bras; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

8.  Quantification of heparin-induced TFPI release: a maximum release at low heparin dose.

Authors:  Michiel J B Kemme; Jacobus Burggraaf; Rik C Schoemaker; Cornelis Kluft; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.